JP2024521897A5 - - Google Patents
Info
- Publication number
- JP2024521897A5 JP2024521897A5 JP2023574349A JP2023574349A JP2024521897A5 JP 2024521897 A5 JP2024521897 A5 JP 2024521897A5 JP 2023574349 A JP2023574349 A JP 2023574349A JP 2023574349 A JP2023574349 A JP 2023574349A JP 2024521897 A5 JP2024521897 A5 JP 2024521897A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- formula
- ribonucleoside
- items
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195993P | 2021-06-02 | 2021-06-02 | |
| US63/195,993 | 2021-06-02 | ||
| PCT/US2022/032014 WO2022256565A2 (en) | 2021-06-02 | 2022-06-02 | Compositions and methods for delivering therapeutic oligonucleotides to the central nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521897A JP2024521897A (ja) | 2024-06-04 |
| JP2024521897A5 true JP2024521897A5 (enExample) | 2025-05-28 |
Family
ID=84324589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574349A Pending JP2024521897A (ja) | 2021-06-02 | 2022-06-02 | 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240287526A1 (enExample) |
| EP (1) | EP4346845A2 (enExample) |
| JP (1) | JP2024521897A (enExample) |
| KR (1) | KR20240038930A (enExample) |
| CN (1) | CN117795069A (enExample) |
| AU (1) | AU2022286420A1 (enExample) |
| CA (1) | CA3222212A1 (enExample) |
| IL (1) | IL308994A (enExample) |
| WO (1) | WO2022256565A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023354001A1 (en) * | 2022-09-28 | 2025-04-17 | Atalanta Therapeutics, Inc. | Compositions and methods for treatment of huntington's disease |
| WO2024169770A1 (zh) * | 2023-02-17 | 2024-08-22 | 苏州时安生物技术有限公司 | 一种抑制SCN9A基因表达的siRNA、其药物组合物及用途 |
| WO2024197280A1 (en) * | 2023-03-23 | 2024-09-26 | Atalanta Therapeutics, Inc. | Compositions and methods for improved gene silencing |
| WO2025111497A1 (en) * | 2023-11-21 | 2025-05-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating acute activation |
| WO2025193786A1 (en) * | 2024-03-12 | 2025-09-18 | University Of Massachusetts | Oligonucleotides for prnp modulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3107549B1 (en) * | 2014-02-20 | 2020-07-01 | B.G. Negev Technologies and Applications Ltd. | Anionic polyplexes for use in the delivery of nucleic acids |
| WO2019122279A1 (en) * | 2017-12-22 | 2019-06-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorodithioate internucleoside linkage |
-
2022
- 2022-06-02 IL IL308994A patent/IL308994A/en unknown
- 2022-06-02 JP JP2023574349A patent/JP2024521897A/ja active Pending
- 2022-06-02 KR KR1020237045431A patent/KR20240038930A/ko active Pending
- 2022-06-02 CN CN202280052900.3A patent/CN117795069A/zh active Pending
- 2022-06-02 CA CA3222212A patent/CA3222212A1/en active Pending
- 2022-06-02 EP EP22816877.9A patent/EP4346845A2/en active Pending
- 2022-06-02 AU AU2022286420A patent/AU2022286420A1/en active Pending
- 2022-06-02 WO PCT/US2022/032014 patent/WO2022256565A2/en not_active Ceased
- 2022-06-02 US US18/566,983 patent/US20240287526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521897A5 (enExample) | ||
| US20230024153A1 (en) | Blood-brain barrier permeable heteroduplex nucleic acid | |
| CA2809637C (en) | Antisense nucleic acids | |
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2021507686A5 (enExample) | ||
| JP2024511473A5 (enExample) | ||
| JP2018528781A5 (enExample) | ||
| WO2018062510A1 (ja) | オーバーハングを有する二本鎖核酸複合体 | |
| JP2016533751A5 (enExample) | ||
| JP2022520986A5 (enExample) | ||
| JP2024041845A (ja) | ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド | |
| EP3769769A1 (en) | Nucleic acid with reduced toxicity | |
| JP2021515784A5 (enExample) | ||
| JP2023518268A5 (enExample) | ||
| JP2023139252A (ja) | 新規のチオホスホラミダイト | |
| CN120129749A (zh) | 靶向微管相关蛋白TAU核酸的siRNA组合物和方法 | |
| CN114901823A (zh) | 诱导外显子50的跳读的反义核酸 | |
| JP7737667B2 (ja) | 核酸複合体 | |
| JP2024041886A (ja) | ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド | |
| JP2024542738A5 (enExample) | ||
| JP2025518487A5 (enExample) | ||
| JP2018518167A5 (enExample) | ||
| JP2024512612A5 (enExample) | ||
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| US20240287512A1 (en) | Lipid conjugation for targeting neurons of the central nervous system |